Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pazopanib vs lapatinib Overall survival · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | HR 0.96 [0.67, 1.38] | 1 study · 152 participants | Low |
Bevacizumab plus chemotherapy vs chemotherapy Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | RR 5 [1.11, 22.56] | 1 study · 440 participants | Low |
Pazopanib vs lapatinib Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | RR 1.03 [0.07, 16.12] | 1 study · 150 participants | Very low |
Pazopanib vs lapatinib Specific adverse events: haemorrhage · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | RR 1.03 [0.31, 3.4] | 1 study · 150 participants | Very low |
Pazopanib vs lapatinib Specific adverse events: thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | RR 3.08 [0.13, 74.42] | 1 study · 150 participants | Very low |
Pazopanib vs lapatinib Specific adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | RR 11.81 [2.89, 48.33] | 1 study · 150 participants | Moderate |
Pazopanib vs lapatinib Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | RR 1.31 [0.83, 2.07] | 1 study · 150 participants | Low |
Pazopanib vs lapatinib Economic evaluation ‐ not measured · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | no estimate extracted | NR | No studies |
Bevacizumab plus chemotherapy vs chemotherapy Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | RR 4.5 [1.55, 13.08] | 1 study · 440 participants | Moderate |
Bevacizumab plus chemotherapy vs chemotherapy Specific adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | RR 13.75 [5.07, 37.29] | 1 study · 440 participants | Moderate |
Bevacizumab plus chemotherapy vs chemotherapy Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | RR 1.44 [1.16, 1.79] | 1 study · 439 participants | Moderate |
Bevacizumab plus chemotherapy vs chemotherapy Economic evaluation · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | no estimate extracted | 1 study · 452 participants | Low |
Cediranib plus chemotherapy vs placebo plus chemotherapy Overall survival · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | HR 0.94 [0.53, 1.65] | 1 study · 69 participants | Low |
Cediranib plus chemotherapy vs placebo plus chemotherapy Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | RR 3.27 [0.14, 77.57] | 1 study · 67 participants | Very low |
Intervention NR All intervention options · people with first recurrence of glioblastoma Interventions: bevacizumab (BEV), BEV + lomustine (LOM), regorafenib… Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR BEV+IRI (1 RCT, 79 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV),… Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis (2021) · Cochrane | RR 2.22 [1.19, 4.18] | 1 study · 79 participants | High |
Intervention NR BEV+VB111 (1 RCT, 128 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV),… Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis (2021) · Cochrane | RR 3.77 [2.25, 6.33] | 1 study · 111 participants | High |
Intervention NR BEV+TRC 105 (1 RCT, 49 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV),… Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis (2021) · Cochrane | RR 6.86 [2.55, 18.41] | 1 study · 105 participants | High |
Intervention NR All intervention options · people with first recurrence of glioblastoma Interventions: bevacizumab (BEV), BEV + lomustine (LOM), regorafenib… Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outcomes (5 RCTs, 1024 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV),… Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | 5 studies · 1024 participants | Ungraded |
Intervention NR BEV(8 RCTs; 498 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV),… Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | 8 studies · 498 participants | Ungraded |
Intervention NR FOM (1 RCT, 32 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV),… Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis (2021) · Cochrane | RR 0.44 [0.11, 1.72] | 1 study · 32 participants | Ungraded |
Intervention NR BEV+HSPPC96 1 RCTs; 53 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV),… Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis (2021) · Cochrane | RR 1.01 [0.33, 3.1] | 1 study · 96 participants | Low |
Intervention NR BEV+ONA(1 RCT; 64 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV),… Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis (2021) · Cochrane | RR 1.17 [0.57, 2.39] | 1 study · 64 participants | Low |
Intervention NR BEV+CAB (1 RCT; 58 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV),… Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis (2021) · Cochrane | RR 1.27 [0.61, 2.66] | 1 study · 58 participants | Low |
Intervention NR BEV+DAS (2 RCTs, 83 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV),… Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis (2021) · Cochrane | RR 0.52 [0.69, 3.34] | 2 studies · 83 participants | High |
iMRI image‐guided surgery vs standard surgery Adverse events · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Neuronavigation image‐guided surgery vs standard surgery Overall survival · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Neuronavigation image‐guided surgery vs standard surgery Progression‐free survival · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Neuronavigation image‐guided surgery vs standard surgery Quality of life · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
iMRI image‐guided surgery vs standard surgery Overall survival · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
iMRI image‐guided surgery vs standard surgery Progression‐free survival · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
iMRI image‐guided surgery vs standard surgery Quality of life · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
5‐ALA image‐guided surgery vs standard surgery Adverse events · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
5‐ALA image‐guided surgery vs standard surgery Overall survival · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
5‐ALA image‐guided surgery vs standard surgery Progression‐free survival · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
5‐ALA image‐guided surgery vs standard surgery Quality of life · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Neuronavigation image‐guided surgery vs standard surgery Adverse events · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Total studies: 9 Total participants: 1757 Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | no estimate extracted | 9 participants | Ungraded |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Dactolisib (1 RCT; 62 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 0.56 [0.13, 2.37] | 1 study · 62 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Total studies: 10 Total participants: 2113 Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | no estimate extracted | 10 participants | Ungraded |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Everolimus (3 RCT; 632 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.36 [0.28, 0.46] | 3 studies · 632 participants | Moderate |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Interferon + SSA (2 RCTs; 468 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.34 [0.14, 0.8] | 2 studies · 468 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Everolimus + SSA (3 RCTs; 739 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.38 [0.26, 0.57] | 3 studies · 739 participants | Low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Bevacizumab + SSA (1 RCT; 402 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.36 [0.15, 0.89] | 1 study · 402 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Interferon (1 RCT; 66 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.41 [0.18, 0.94] | 1 study · 66 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Sunitinib (1 RCT; 171 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.42 [0.26, 0.67] | 1 study · 171 participants | Moderate |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Everolimus + bevacizumab + SSA (1 RCT; 150 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.48 [0.28, 0.83] | 1 study · 150 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Surufatinib (1 RCT; 172 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | HR 0.49 [0.32, 0.76] | 1 study · 172 participants | High |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Everolimus (3 RCTs; 632 participants) Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane | OR 3.29 [2.21, 4.9] | 3 studies · 632 participants | Moderate |